Page last updated: 2024-11-04

acetylcarnitine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Acetylcarnitine is a naturally occurring compound that plays a crucial role in energy production within cells. It is synthesized in the body from the amino acid L-carnitine and acetate. Acetylcarnitine is involved in transporting long-chain fatty acids into mitochondria, the powerhouses of cells, where they are broken down to generate energy. It is also believed to have antioxidant properties, protecting cells from damage caused by free radicals. Research suggests that acetylcarnitine may have various potential benefits, including improving cognitive function, enhancing athletic performance, and supporting cardiovascular health. Its role in energy metabolism and its potential to protect against oxidative stress make it a subject of ongoing research. It is being investigated for its potential therapeutic applications in conditions such as Alzheimer's disease, Parkinson's disease, and heart failure.'

O-acetyl-L-carnitine : An O-acyl-L-carnitine where the acyl group specified is acetyl. It facilitates movement of acetyl-CoA into the matrices of mammalian mitochondria during the oxidation of fatty acids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7045767
CHEMBL ID1697733
CHEBI ID57589
SCHEMBL ID118455
MeSH IDM0000161
PubMed CID1
CHEBI ID73024
SCHEMBL ID69781
MeSH IDM0000161

Synonyms (83)

Synonym
acetyl-l-(-)-carnitine
l-o-acetylcarnitine
l-carnitine acetyl ester
1-propanaminium, 2-(acetyloxy)-3-carboxy-n,n,n-trimethyl-, hydroxide, inner salt, (r)-
(-)-acetylcarnitine
(r)-acetylcarnitine
r-acetylcarnitine
l-acetylcarnitine
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate, l-
alcar
o-acetyl-l-carnitine
acetyl-l-carnitine
levocarnitine acetyl
(3r)-3-(acetyloxy)-4-(trimethylammonio)butanoate
3040-38-8
(-)o-acetylcarnitine
(3r)-3-(acetyloxy)-4-(trimethylazaniumyl)butanoate
o-acetyl-(r)-carnitine
CHEBI:57589 ,
(3r)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
CHEMBL1697733
acetyl l carnitine
l-acetyl carnitine
hsdb 7587
acetylcarnitine, l-
6dh1w9vh8q ,
carnitine, acetyl-, l-
unii-6dh1w9vh8q
gtpl4520
(2r)-2-(acetyloxy)-3-carboxy-n,n,n-trimethyl-1-propanaminium inner salt
DB08842
l-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt acetate
acetylcarnitine [vandf]
acetylcarnitine [mi]
acetyl l-carnitine
acetylcarnitine [who-dd]
vitamin bt, acetate
acetyl-l-carnitine [hsdb]
acetyl carnitine [inci]
oristar acc
SCHEMBL118455
1-propanaminium, 2-(acetyloxy)-3-carboxy-n,n,n-trimethyl-, inner salt, (2r)-
DTXSID1040956
LMFA07070050
acetyl-carnitine
(+-)-acetylcarnitine
(r)-3-acetoxy-4-(trimethylammonio)butanoate
Q311992
AKOS040747759
1-propanaminium, 2-(acetoxy)-3-carboxy-n,n,n-trimethyl-, hydroxide, inner salt, (+-)-
acetyl-dl-carnitine
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate, dl-
dl-o-acetylcarnitine
acetylcarnitine
acetyl carnitine
BMSE000142
1-propanaminium, 2-(acetoxy)-3-carboxy-n,n,n-trimethyl-, hydroxide, inner salt, (+-)- (9ci)
3-acetyloxy-4-(trimethylazaniumyl)butanoate
unii-07op6h4v4a
07op6h4v4a ,
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate
dl-acetylcarnitine
2-(acetyloxy)-3-carboxy-n,n,n-trimethyl-1-propanaminium inner salt
(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt acetate
acetylcarnitine, (+/-)-
o-acetyl-dl-carnitine
acetylcarnitine, dl-
acetylcarnitine racemate [mi]
acetylcarnitine dl-form
SCHEMBL69781
DTXSID2048117
CHEBI:73024
3-(acetyloxy)-4-(trimethylammonio)butanoate
870-77-9
3-(acetyloxy)-4-(trimethylazaniumyl)butanoate
LMFA07070060
HY-126358
Q27140241
(+/-)-acetylcarnitine
FT-0778235
CS-0102945
AS-82719
d/l -acetyl-carnitine

Research Excerpts

Overview

L-Acetylcarnitine (ALCAR) is an acetic acid ester of carnitine that has higher bioavailability and is considered a fat-burning energizer supplement. L-acetylc Carnitine is a compound with cholinergic properties and putative action on the visual system and glucose metabolism.

ExcerptReferenceRelevance
"l-Acetylcarnitine (ALCAR) is an acetic acid ester of carnitine that has higher bioavailability and is considered a fat-burning energizer supplement."( Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways.
Albini, A; Baci, D; Bassani, B; Bruno, A; Mortara, L; Noonan, DM; Tramacere, M, 2018
)
1.04
"L: -Acetylcarnitine (LAC) is a physiologically active substance that improves both the energetic and the neurotransmission profiles."( Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial.
Astuto, M; Lo Giudice, E; Malaguarnera, M; Pistone, G; Raffaele, R; Rampello, L; Vecchio, I, 2006
)
1.18
"Acetylcarnitine is an endogenous substance, active in the CNS, but its exact role in neurotransmission is still unknown. "( Stereospecific effects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine and serotonin.
Janiri, L; Pirrongelli, C; Tempesta, E, 1985
)
2.01
"L-acetylcarnitine is a compound with cholinergic properties and putative action on the visual system and the glucose metabolism. "( Effects of intravenous L-acetylcarnitine on retinal oscillatory potentials.
Lopez, L; Maggi, L; Rosadini, G; Sannita, WG, 1988
)
1.3

Effects

ExcerptReferenceRelevance
"Acetylcarnitine has been identified as one of several urinary biomarkers indicative of radiation exposure in adult rhesus macaque monkeys (non-human primates, NHPs). "( Differential mobility spectrometry (DMS) reveals the elevation of urinary acetylcarnitine in non-human primates (NHPs) exposed to radiation.
Chen, Z; Coy, SL; Erion, DM; Fornace, AJ; Laiakis, EC; Pannkuk, E; Pfefferkorn, JA; Vera, NB; Vouros, P, 2018
)
2.15

Actions

L-acetylcarnitine plays a key role in sperm metabolism and in the whole spermatogenetic process. Acetylc Carnitine can be detected in proton magnetic resonance spectra in skeletal muscle.

ExcerptReferenceRelevance
"Acetylcarnitine plays an important role in fat metabolism and can be detected in proton magnetic resonance spectra in skeletal muscle. "( Muscle-Specific Relation of Acetylcarnitine and Intramyocellular Lipids to Chronic Hyperglycemia: A Pilot 3-T
Bastian, M; Kautzky-Willer, A; Klepochová, R; Krebs, M; Krššák, M; Leutner, M; Trattnig, S; Weber, M, 2020
)
2.29
"L-acetylcarnitine plays a key role in sperm metabolism and in the whole spermatogenetic process. "( Effects of L-acetylcarnitine (LAC) on the post-injury recovery of mouse spermatogenesis monitored by flow cytometry. 1. Recovery after X-irradiation.
Amendola, R; Bartoleschi, C; Cordelli, E; Mauro, F; Spanò, M; Uccelli, R,
)
1.22

Treatment

L-acetylcarnitine treatment enhanced mGlu2/3 receptor protein levels in the dorsal region of the spinal cord. Treatment with acetylc Carnitine (AcCN) increases the activity of cytochrome oxidase in the aged heart.

ExcerptReferenceRelevance
"L-acetylcarnitine treatment enhanced mGlu2/3 receptor protein levels in the dorsal region of the spinal cord."( Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain.
Battaglia, G; Bernabucci, M; Bruno, V; Cannella, M; Gradini, R; Imbriglio, T; Mascio, G; Nicoletti, F; Notartomaso, S; Scarselli, P; Zappulla, C, 2017
)
1.27
"L-acetylcarnitine-treated animals show significantly higher twitch and tetanic tensions of re-innervated muscle."( L-acetylcarnitine enhances functional muscle re-innervation.
Brunetti, O; Carobi, C; Della Torre, G; Grassi, S; Pettorossi, VE, 1991
)
1.56
"Treatment with acetylcarnitine (AcCN) increases the activity of cytochrome oxidase in the aged heart."( Reversal of mitochondrial defects before ischemia protects the aged heart.
He, D; Hoppel, CL; Lesnefsky, EJ; Moghaddas, S, 2006
)
0.67

Toxicity

Peripheral neuropathy is a recognized side effect of microtubule-targeting agents. acetyl L-carnitine co-treatment prevented ketamine-induced adverse effects on the RB neurons.

ExcerptReferenceRelevance
" Since at least part of the toxic action of MPP+ is related to mitochondrial inhibition, the partial reversal of the inhibition of MTT response by ALC could involve a partial restoration of mitochondrial function."( Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine.
Ali, SF; Binienda, Z; Duhart, H; Gaetani, F; Virmani, A; Xu, A, 2004
)
0.32
" Since at least part of the toxic action of MPP+ is related to mitochondrial inhibition, the partial reversal of the inhibition of MTT response by ALC could involve a partial restoration of mitochondrial function."( Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine.
Ali, SF; Binienda, Z; Duhart, H; Gaetani, F; Virmani, A; Xu, A, 2004
)
0.32
" GSH plays a key role in antioxidant defense, and HNE exposure causes an initial depletion of GSH that leads to gradual toxic accumulation of reactive oxygen species."( Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
Abdul, HM; Butterfield, DA, 2007
)
0.34
" GSH plays a key role in antioxidant defense, and HNE exposure causes an initial depletion of GSH that leads to gradual toxic accumulation of reactive oxygen species."( Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
Abdul, HM; Butterfield, DA, 2007
)
0.34
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons."( Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Bennett, GJ; Xiao, WH; Zheng, H, 2012
)
0.38
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons."( Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Bennett, GJ; Xiao, WH; Zheng, H, 2012
)
0.38
" However, acetyl L-carnitine co-treatment prevented ketamine-induced adverse effects on the RB neurons."( Acetyl L-carnitine protects motor neurons and Rohon-Beard sensory neurons against ketamine-induced neurotoxicity in zebrafish embryos.
Ali, SF; Cuevas, E; Guo, X; Kanungo, J; Paule, MG; Trickler, WJ,
)
0.13
" However, acetyl L-carnitine co-treatment prevented ketamine-induced adverse effects on the RB neurons."( Acetyl L-carnitine protects motor neurons and Rohon-Beard sensory neurons against ketamine-induced neurotoxicity in zebrafish embryos.
Ali, SF; Cuevas, E; Guo, X; Kanungo, J; Paule, MG; Trickler, WJ,
)
0.13
"Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)."( A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013
)
0.39
"Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)."( A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013
)
0.39
" Thus, clinically relevant concentrations of propofol induce dose-dependent adverse effects on rat embryonic neural stem cells by slowing or stopping cell division/proliferation and causing cellular damage."( Protective effect of acetyl-L-carnitine on propofol-induced toxicity in embryonic neural stem cells.
Fogle, CM; Hanig, JP; Liu, F; Patterson, TA; Paule, MG; Rainosek, SW; Sadovova, N; Slikker, W; Wang, C, 2014
)
0.4
" Thus, clinically relevant concentrations of propofol induce dose-dependent adverse effects on rat embryonic neural stem cells by slowing or stopping cell division/proliferation and causing cellular damage."( Protective effect of acetyl-L-carnitine on propofol-induced toxicity in embryonic neural stem cells.
Fogle, CM; Hanig, JP; Liu, F; Patterson, TA; Paule, MG; Rainosek, SW; Sadovova, N; Slikker, W; Wang, C, 2014
)
0.4
" Furthermore, combination therapy provides less adverse effects."( [Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit].
Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB, 2015
)
0.42
" Furthermore, combination therapy provides less adverse effects."( [Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit].
Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB, 2015
)
0.42
" Adverse drug-drug interaction effects between ketamine and CsA have been reported in mammals and humans."( Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.
Ali, SF; Dumas, M; Gu, Q; Kanungo, J; Paule, MG; Robinson, BL, 2017
)
0.46
" Adverse drug-drug interaction effects between ketamine and CsA have been reported in mammals and humans."( Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.
Ali, SF; Dumas, M; Gu, Q; Kanungo, J; Paule, MG; Robinson, BL, 2017
)
0.46
" Stimulation of spermatogenesis using the antioxidant complex SpermActin Forte is an effective and safe method of treating male infertility."( [Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility].
Gamidov, SI; Ovchinnikov, RI; Popova, AY, 2019
)
0.51
" Stimulation of spermatogenesis using the antioxidant complex SpermActin Forte is an effective and safe method of treating male infertility."( [Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility].
Gamidov, SI; Ovchinnikov, RI; Popova, AY, 2019
)
0.51
" To the best of our knowledge, these studies for the first time show that nifedipine and the dietary supplement ALCAR together induce adverse effects while providing evidence on the therapeutic efficacy of subanesthetic doses of ketamine against nifedipine toxicity in vivo."( Nifedipine toxicity is exacerbated by acetyl l-carnitine but alleviated by low-dose ketamine in zebrafish in vivo.
Ali, SF; Dumas, M; Gu, Q; Kanungo, J; Robinson, BL; Tryndyak, V, 2020
)
0.56
" To the best of our knowledge, these studies for the first time show that nifedipine and the dietary supplement ALCAR together induce adverse effects while providing evidence on the therapeutic efficacy of subanesthetic doses of ketamine against nifedipine toxicity in vivo."( Nifedipine toxicity is exacerbated by acetyl l-carnitine but alleviated by low-dose ketamine in zebrafish in vivo.
Ali, SF; Dumas, M; Gu, Q; Kanungo, J; Robinson, BL; Tryndyak, V, 2020
)
0.56
" The antioxidants in question markedly ameliorated serum interleukin-1β and tumor necrosis factor-α, and brain NO, lipid peroxide, glutathione, and superoxide dismutase levels as well as protein expression of brain-derived neurotrophic factor (BDNF) and P-cyclic-AMP response element-binding protein (CREB) that were altered by a toxic dose of PRA, as well as histopathological alterations, including improvement of the cerebellum architecture."( Neuroprotective efficacy of nano-CoQ against propionic acid toxicity in rats: Role of BDNF and CREB protein expressions.
Alanazi, K; Alesikri, M; Alhusaini, A; Almarshad, S; Almasoud, R; Alrumayyan, B; Hasan, IH, 2020
)
0.56
" The antioxidants in question markedly ameliorated serum interleukin-1β and tumor necrosis factor-α, and brain NO, lipid peroxide, glutathione, and superoxide dismutase levels as well as protein expression of brain-derived neurotrophic factor (BDNF) and P-cyclic-AMP response element-binding protein (CREB) that were altered by a toxic dose of PRA, as well as histopathological alterations, including improvement of the cerebellum architecture."( Neuroprotective efficacy of nano-CoQ against propionic acid toxicity in rats: Role of BDNF and CREB protein expressions.
Alanazi, K; Alesikri, M; Alhusaini, A; Almarshad, S; Almasoud, R; Alrumayyan, B; Hasan, IH, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" The proposed method was applied to the pharmacokinetic studies of an active metabolite and open-ring metabolites after oral administration of a penem antibiotic, FCE22891, in dogs."( Simultaneous determination of an active metabolite and open-ring metabolites by high performance liquid chromatography and pharmacokinetic studies of a penem antibiotic, FCE22891, in dogs.
Banno, K; Imado, N; Maki, T; Matsuoka, M; Sato, T, 1998
)
0.3
" The elimination half-life of L-carnitine and the time required to reach the Cmax (Tmax) was 60."( Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers.
Cao, Y; Han, ZW; Liu, CJ; Wang, CB; Wang, LX; Wang, YX, 2009
)
0.35
" L-carnitine also has a longer half-life than ALC and PLC."( Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers.
Cao, Y; Han, ZW; Liu, CJ; Wang, CB; Wang, LX; Wang, YX, 2009
)
0.35
"This study was designed to assess the pharmacokinetic (PK) bioequivalence between a new generic (test) formulation of ALC hydrochloride 590 mg and a branded (reference) formulation of ALC hydrochloride 590 mg in healthy Korean male volunteers."( Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers.
Baek, SM; Hwang, DY; Kim, BH; Seo, EJ; Zheng, R, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" Adverse drug-drug interaction effects between ketamine and CsA have been reported in mammals and humans."( Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.
Ali, SF; Dumas, M; Gu, Q; Kanungo, J; Paule, MG; Robinson, BL, 2017
)
0.46
"To investigate the efficacy and safety of the L- and acetyl-L-carnitine complex, vitamins A, E, C, selenium, zinc and other antioxidants ("SpermActin" + "More than vitamins") in combination with clomiphene citrate (CC) in managing male idiopathic infertility in the form of oligo, and/or astheno-, and/or teratozoospermia."( [Using L- and acetyl-L-carnintines in combination with clomiphene citrate and antioxidant complex for treating idiopathic male infertility: a prospective randomized trial].
Bozhedomov, VA; Bozhedomova, GE; Komarina, RA; Lipatova, NA; Rokhlikov, IM; Shcherbakova, EV, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of dietary L-carnitine is 54-87% and is dependent on the amount of L-carnitine in the meal."( Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism.
Rebouche, CJ, 2004
)
0.32
"This study was undertaken to investigate the bioavailability of various L-carnitine esters (acetyl-L-carnitine and lauroyl-L-carnitine) and salts (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate) relative to base of free L-carnitine."( Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds.
Becker, K; Eder, K; Felgner, J; Kluge, H, 2005
)
0.33
"To overcome the problem of poor aqueous solubility and bioavailability of indirubin-3-oximes, the compounds were modified by attaching a quaternary ammonium group at the oxime moiety."( Water-soluble cationic derivatives of indirubin, the active anticancer component from Indigo naturalis.
Arion, VB; Berger, W; Egger, A; Galanski, M; Ginzinger, W; Jakupec, MA; Keppler, BK; Mühlgassner, G, 2012
)
0.38
" Our results also showed that the delivery routes differently affected the bioavailability of administered [(14)C]d-met as well as the concentrations of methionine, ALCAR and the ratio of oxidized to reduced glutathione."( Pulmonary delivery of d-methionine is associated with an increase in ALCAR and glutathione in cochlear fluids.
Altshul, L; Bortoni, ME; Brain, JD; Clifford, R; Cotanche, DA; Forsberg, S; Grondin, Y; Jackson, RL; Labrecque, B; Manneberg, O; Molina, R; Rogers, RA; Sepulveda, R; Treviño-Villarreal, JH, 2013
)
0.39
" l-Acetylcarnitine (ALCAR) is an acetic acid ester of carnitine that has higher bioavailability and is considered a fat-burning energizer supplement."( Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways.
Albini, A; Baci, D; Bassani, B; Bruno, A; Mortara, L; Noonan, DM; Tramacere, M, 2018
)
1.1

Dosage Studied

ExcerptRelevanceReference
" After dosing propionyl-L-carnitine rapidly increased, and then decreased reaching the base value within 6 h or more, depending on the species and the dose."( Homeostatic equilibrium of L-carnitine family before and after i.v. administration of propionyl-L-carnitine in humans, dogs and rats.
Arrigoni Martelli, E; Bassani, E; Cardace, G; Corbelleta, C; Marzo, A; Morabito, E, 1991
)
0.28
" The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement."( Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia.
Campi, N; Scarzella, L; Todeschini, GP,
)
0.66
"The effects of long-term dosing with acetyl-L-carnitine (ALC) were examined in aged rats, and they were compared with those in young rats."( Effects of acetyl-L-carnitine on the brain lipofuscin content and emotional behavior in aged rats.
Anami, K; Fujii, T; Kohjimoto, Y; Kuwaki, T; Matsumoto, M; Ogawa, T; Ono, T; Satoh, H; Shirakawa, K; Yasuda, H, 1988
)
0.27
" In the latter the drug also proved active when administered orally in the 3-100 mg/kg dosage range."( Effect of acetyl-L-carnitine on conditioned reflex learning rate and retention in laboratory animals.
Bossoni, G; Carpi, C, 1986
)
0.27
" Further work is needed to define the mechanism by which exogenous carnitine improves exercise performance in order to better define potential patient populations for therapy and to facilitate optimal dosing regimens."( Carnitine metabolism during exercise.
Brass, EP; Hiatt, WR, 1994
)
0.29
" The predialysis and postdialysis plasma levels of L-carnitine decreased once dosing was ceased but had not returned to pretreatment levels after 6 weeks."( Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans, AM; Faull, R; Fornasini, G; Lemanowicz, EF; Longo, A; Nation, RL; Pace, S, 2000
)
0.31
" The dose-response curve was represented by a second-degree polynomial without absolute term."( Effect of acetyl-L-carnitine on leukemia L1210 resistant to mitoxantrone.
Mĕlka, M; Niang, M, 2000
)
0.31
" LAC (or placebo) was started intramuscularly at a dosage of 1000 mg/day for 10 days and continued orally at a dosage of 2000 mg/day for the remainder of the study (355 days)."( Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study.
De Grandis, D; Minardi, C, 2002
)
0.31
" In this study we examined the dose-response effect of ALCAR on the primary sensory neurons in the rat dorsal root ganglia (DRG) 2 weeks after sciatic nerve axotomy."( Primary sensory neuronal rescue with systemic acetyl-L-carnitine following peripheral axotomy. A dose-response analysis.
Brannstrom, T; Hart, A; Terenghi, G; Wiberg, M; Wilson, AD, 2003
)
0.32
" Rats received daily acetyl-L-carnitine at a dosage of 75 mg/kg body weight orally during exposure."( Acetyl-L-carnitine ameliorates hypobaric hypoxic impairment and spatial memory deficits in rats.
Barhwal, K; Hota, SK; Ilavazhagan, G; Jayalakshmi, K; Singh, SB, 2007
)
0.34
" While earlier no treatment was available, in the recent decade an antioxidant therapy became very popular using combinations of high dosage antioxidant vitamins C, E, beta carotene and zinc."( [Metabolic therapy for early treatment of age-related macular degeneration].
Corrado Balacco, G; Fehér, J; Kovács, B; Kovács, I; Schvöller, M, 2007
)
0.34
" These data may have important implications in the designing of dosing regimens for L-carnitine or its analogues, such as ALC or PLC."( Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers.
Cao, Y; Han, ZW; Liu, CJ; Wang, CB; Wang, LX; Wang, YX, 2009
)
0.35
" The hormetic dose-response, challenges long-standing beliefs about the nature of the dose-response in a low dose zone, having the potential to affect significantly the design of pre-clinical studies and clinical trials as well as strategies for optimal patient dosing in the treatment of numerous diseases."( Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis.
Calabrese, EJ; Calabrese, V; Cornelius, C; Dinkova-Kostova, AT,
)
0.4
" The inhibition of TNF-alpha could be improved by ALC and in a dose-response relation."( [Effect of acetyl-L-carnitine on the insulin resistance of L6 cells induced by tumor necrosis factor-alpha].
Dai, X; Ding, Y; Li, Y; Wang, J; Zhang, Z; Zhao, M, 2010
)
0.36
"Randomized, double-blind, placebo-controlled, pilot study in 64 alcohol-dependent anhedonic patients: 23 received ALC at a dose of 3 g/day, 21 received ALC at a dosage of 1 g/day and 20 were given placebo."( Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial.
Andreoli, S; D'Iddio, S; Di Nicola, M; Iannoni, E; Janiri, L; Martinotti, G; Ortolani, I; Pozzi, G; Reina, D; Tedeschi, D,
)
0.13
"Sixty-four anhedonic alcohol dependent patients with minor or absent withdrawal symptoms were randomized: 23 received ALC at a dosage of 3g/day, 21 received ALC at a dosage of 1g/day, and 20 were given placebo."( Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects.
Andreoli, S; D'Iddio, S; Di Nicola, M; Fanella, F; Iannoni, E; Martinotti, G; Ortolani, I; Pozzi, G; Prof, LJ; Reina, D; Tedeschi, D, 2011
)
0.37
" Mice treated with DMH were dosed orally with curcumin and/or carnitine and acylcarnitines for 20 weeks."( Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model.
Aurisicchio, L; Ciliberto, G; Di Napoli, A; Mancini, R; Marra, E; Mori, F; Roscilli, G; Serlupi-Crescenzi, O; Virmani, A, 2013
)
0.39
" Despite intensive research, the quest for promising neuroprotective drugs has largely failed, not only because of ineffectiveness, but also because of serious side-effects and dosing difficulties."( Acetyl-L-carnitine normalizes the impaired long-term potentiation and spine density in a rat model of global ischemia.
Farkas, T; Gellért, L; Iwamori, N; Kis, Z; Knapp, L; Kocsis, K; Oláh, G; Ono, E; Takakuwa, H; Toldi, J, 2014
)
0.4
" Animals were dosed orally for 28 successive days."( Effect of Acetyl-L-Carnitine on Antioxidant Status, Lipid Peroxidation, and Oxidative Damage of Arsenic in Rat.
Kazemi, AR; Omidi, A; Razavi-Azarkhiavi, K; Sabzevari, O; Sabzevari, S; Sepand, MR; Zirak, MR, 2016
)
0.43
" Concentrations required for effective simvastatin- or resveratrol-induced inhibition of mitochondrial respiration were found much higher than concentrations achieved under standard dosing of these drugs."( Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration.
Fišar, Z; Hroudová, J; Kopřivová, A; Macečková, D; Singh, N, 2016
)
0.67
" Previous work has demonstrated an up-regulated dose-response profile in a balanced male/female NHP cohort."( Differential mobility spectrometry (DMS) reveals the elevation of urinary acetylcarnitine in non-human primates (NHPs) exposed to radiation.
Chen, Z; Coy, SL; Erion, DM; Fornace, AJ; Laiakis, EC; Pannkuk, E; Pfefferkorn, JA; Vera, NB; Vouros, P, 2018
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
O-acetylcarnitineAn O-acylcarnitine having acetyl as the acyl substituent.
saturated fatty acyl-L-carnitineAn O-acylcarnitine in which the R is a saturated fatty acyl chain.
O-acylcarnitineAny carboxylic ester obtained by the O-acylation of carnitine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
carnitine shuttle34
Oxidation of Branched-Chain Fatty Acids1122
Beta Oxidation of Very Long Chain Fatty Acids1013
Adrenoleukodystrophy, X-Linked1013
Carnitine-Acylcarnitine Translocase Deficiency1013

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 5Homo sapiens (human)Km8.50002.66005.58008.5000AID681169
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
sodium ion transportSolute carrier family 22 member 5Homo sapiens (human)
response to symbiotic bacteriumSolute carrier family 22 member 5Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 5Homo sapiens (human)
carnitine transportSolute carrier family 22 member 5Homo sapiens (human)
response to type II interferonSolute carrier family 22 member 5Homo sapiens (human)
response to tumor necrosis factorSolute carrier family 22 member 5Homo sapiens (human)
positive regulation of intestinal epithelial structure maintenanceSolute carrier family 22 member 5Homo sapiens (human)
sodium-dependent organic cation transportSolute carrier family 22 member 5Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transportSolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 5Homo sapiens (human)
carnitine transmembrane transportSolute carrier family 22 member 5Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
protein bindingSolute carrier family 22 member 5Homo sapiens (human)
ATP bindingSolute carrier family 22 member 5Homo sapiens (human)
amino-acid betaine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
carnitine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
symporter activitySolute carrier family 22 member 5Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 5Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytoplasmSolute carrier family 22 member 5Homo sapiens (human)
endoplasmic reticulumSolute carrier family 22 member 5Homo sapiens (human)
cytosolSolute carrier family 22 member 5Homo sapiens (human)
plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
brush border membraneSolute carrier family 22 member 5Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID679144TP_TRANSPORTER: uptake in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID680378TP_TRANSPORTER: inhibition of carnitine uptake by Acetyl-L-carnitine at 5uM in Octn2-HEK cells2000The Journal of biological chemistry, Dec-22, Volume: 275, Issue:51
Molecular and functional characterization of organic cation/carnitine transporter family in mice.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID678795TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID681169TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID680965TP_TRANSPORTER: inhibition of carnitine uptake by Acetyl-L-carnitine at 5uM in Octn3-HEK cells2000The Journal of biological chemistry, Dec-22, Volume: 275, Issue:51
Molecular and functional characterization of organic cation/carnitine transporter family in mice.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID681271TP_TRANSPORTER: inhibition of carnitine transport by Acetyl-L-carnitine at 5uM in Xenopus laevis oocytes2002The Journal of biological chemistry, Sep-27, Volume: 277, Issue:39
Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition.
AID681714TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Acetyl-L-carnitine: 500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,260)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990208 (16.51)18.7374
1990's320 (25.40)18.2507
2000's298 (23.65)29.6817
2010's339 (26.90)24.3611
2020's95 (7.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials160 (11.95%)5.53%
Reviews1 (12.50%)6.00%
Reviews114 (8.51%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies27 (2.02%)4.05%
Observational0 (0.00%)0.25%
Observational5 (0.37%)0.25%
Other7 (87.50%)84.16%
Other1,033 (77.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01223768]0 participants Interventional2002-07-31Completed
ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY [NCT01223742]0 participants Interventional2002-06-30Completed
Comparison of Acetyl- L- Carnitine and Folic Acid Versus Coenzyme Q10 and Folic Acid on Semen and Hormonal Parameters and Semen Oxidative Status in Patients of Primary Infertility. A Double Blind Randomized Clinical Trial [NCT05616000]Phase 286 participants (Actual)Interventional2022-08-06Completed
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) [NCT01381354]Phase 138 participants (Actual)Interventional2010-10-31Completed
Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Assess the Efficacy and Safety of Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer [NCT01379976]Phase 3107 participants (Actual)Interventional2011-04-30Terminated(stopped due to Recruitment was prematurely stopped due to difficulty of recruitment encountered by the experimental centers)
A Phase II Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL [NCT02598622]Phase 28 participants (Actual)Interventional2009-09-30Terminated(stopped due to Drug availability)
[NCT02173132]Phase 394 participants (Actual)Interventional2010-04-30Completed
A Randomized, Phase II/III Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS [NCT06126315]Phase 2/Phase 3246 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy [NCT01223729]67 participants Interventional2002-04-30Completed
Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. [NCT02141035]Phase 2/Phase 320 participants (Actual)Interventional2015-09-30Completed
Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis [NCT02538146]Early Phase 13 participants (Actual)Interventional2015-08-31Terminated(stopped due to Older participants could not tolerate the acidity of the product and withdrew.)
A Prospective, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effect of 6-month Acetylcarnitine Therapy on Arterial Blood Pressure, Lipid and Metabolic Profile, and Kidney Function in Hypertensive Patients With Type 2 Diabetes on Backg [NCT00984750]Phase 3229 participants (Actual)Interventional2008-04-30Completed
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy. [NCT00751205]Phase 2150 participants (Actual)Interventional2008-08-31Completed
Phase II Trial of Bortezomib, Low Dose Dexamethasone, and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma [NCT00581919]Phase 232 participants (Actual)Interventional2004-02-29Completed
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder: A Randomized, Placebo-Controlled Trial of Acetyl-L-Carnitine and Alpha-Lipoic Acid for the Treatment of Bipolar Depression [NCT00719706]Phase 240 participants (Actual)Interventional2008-08-31Completed
Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial [NCT04113889]Phase 2147 participants (Actual)Interventional2019-10-15Completed
Effect of Supplementation of Antioxidant Substances and Probiotics in HCV Correlated Liver Disease Treated With Interferon and Ribavirin. Studies on Biochemical and Virological Response and on Quality of Life. [NCT01909557]Phase 362 participants (Actual)Interventional2010-01-31Completed
[NCT01913964]Phase 40 participants Interventional1997-10-31Completed
Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia [NCT04623619]100 participants (Anticipated)Interventional2020-12-15Not yet recruiting
Acetyl-L-carnitine Supplementation for Co-occurring Depression and Alcohol Use Disorder in Adolescents: A Randomized Placebo-Controlled Pilot Study [NCT05355311]Phase 150 participants (Anticipated)Interventional2023-06-30Not yet recruiting
Assessment of Chronic Fatigue Syndrome as a Mitochondrial Disorder [NCT01872351]0 participants (Actual)Observational2011-11-30Withdrawn(stopped due to PI left the institution)
The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS [NCT05767515]120 participants (Anticipated)Interventional2023-04-15Not yet recruiting
A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer [NCT01492920]Phase 30 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to Withdrawn)
Comparison of G-Series Media System With Antioxidants Versus Standard G-Series Media System [NCT02999958]128 participants (Actual)Interventional2016-12-31Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease [NCT02955706]Phase 4265 participants (Actual)Interventional2016-04-01Completed
Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease [NCT04346862]Phase 4636 participants (Anticipated)Interventional2016-01-26Recruiting
Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock [NCT00592488]Phase 1/Phase 213 participants (Actual)Interventional2006-08-31Completed
Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study [NCT01515839]100 participants (Actual)Interventional2009-05-31Completed
Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. [NCT01524861]Phase 490 participants (Actual)Interventional2011-12-31Completed
Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce [NCT01526564]Phase 3239 participants (Actual)Interventional2008-08-31Completed
Adding Antioxidants Into Human Embryo Culture Media [NCT02971878]128 participants (Actual)Interventional2016-11-30Completed
A Pilot Study to Evaluate the Short-term Effects of Acetyl-carnitine on Insulin Resistance and the Metabolic Syndrome in Patients at Increased Risk of Type 2 Diabetes: Acetyl-carnitine in Insulin Resistance [NCT00393770]Phase 243 participants (Actual)Interventional2004-02-29Completed
An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy [NCT00050271]27 participants (Actual)InterventionalCompleted
A Randomised Double Blinded Placebo Controlled Pilot Study to Evaluate the Safety and Efficacy of Acetyl L Carnitine in Combination With Antiretroviral Therapy for the Prevention of Distal Symmetric Polyneuropathy and Lipid Abnormalities in Treatment naïv [NCT00225160]Phase 250 participants Interventional2003-11-30Active, not recruiting
S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III [NCT00775645]Phase 3437 participants (Actual)Interventional2009-09-30Completed
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia [NCT01921868]20 participants (Anticipated)Interventional2013-08-31Recruiting
Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy: A Randomized, Controlled, Open-label, Phase 2 Trail [NCT05601479]Phase 2100 participants (Anticipated)Interventional2022-11-01Not yet recruiting
An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers [NCT01537549]Phase 1/Phase 211 participants (Actual)Interventional2010-09-14Completed
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease [NCT01054768]Phase 237 participants (Actual)Interventional2009-08-31Completed
Comparative Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Acute Aluminium Phosphide Poisoning: A Clinical Trial [NCT04509258]Phase 4100 participants (Anticipated)Interventional2020-10-31Not yet recruiting
Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study [NCT01695317]Phase 472 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00581919 (3) [back to overview]Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR
NCT00581919 (3) [back to overview]Overall Survival
NCT00581919 (3) [back to overview]Progression-free Survival
NCT00592488 (3) [back to overview]Mean Arterial Blood Pressure
NCT00592488 (3) [back to overview]Serum Lactate
NCT00592488 (3) [back to overview]Vasopressor Dose
NCT00719706 (5) [back to overview]Clinical Global Impression-Severity
NCT00719706 (5) [back to overview]Phosphorus MRS Scans on 4T Scanner
NCT00719706 (5) [back to overview]The 25-Item Hamilton Depression Rating Scale.
NCT00719706 (5) [back to overview]The Montgomery-Asberg Depression Rating Scale
NCT00719706 (5) [back to overview]The Young Mania Rating Scale
NCT00775645 (4) [back to overview]12-week FACIT-fatigue Model-adjusted Score in ALC and Placebo Groups
NCT00775645 (4) [back to overview]12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups
NCT00775645 (4) [back to overview]12-week FACT-Trial Outcome Index(TOI) Functional Status Model-adjusted Score in ALC and Placebo Groups
NCT00775645 (4) [back to overview]Proportion of Patients Experiencing Grade 3 or 4 Neuropathy
NCT01054768 (1) [back to overview]C-Reactive Protein
NCT01537549 (2) [back to overview]Adverse Events
NCT01537549 (2) [back to overview]Cerebral Oxidative Stress Markers
NCT01695317 (2) [back to overview]Days With Migraine and Side Effects
NCT01695317 (2) [back to overview]Headache Days

Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR

"Anti-tumor responses were analyzed descriptively and summarized in tabular format. Ninety percent confidence intervals for the percentage of subjects with a confirmed anti-tumor response were constructed using the method proposed by Duffy-Santner.~Complete response defined as: no evidence of M-protein on immunofixation of serum and/or urine AND less than 5% plasma cells in the bone marrow biopsy.~Partial response defined as: 50 to 99% decrease in M-protein on serum and/or urine protein electrophoresis." (NCT00581919)
Timeframe: Every 21 days, up to 24 weeks

Interventionpercentage of participants (Number)
Bort, Dex, and Dox With ALCAR53

[back to top]

Overall Survival

(NCT00581919)
Timeframe: From date of randomization until the date of death from any cause, assessed up to 7 years

Interventionmonths (Median)
Bort, Dex, and Dox With ALCAR28.3

[back to top]

Progression-free Survival

Progression is defined as any of the following: 1) 25% or greater increase in M-protein as measured by serum or urine protein electrophoresis. There must be an absolute minimum increase of 0.5 g/dl in serum M spike or 0.2 gram of specific urinary light chains to constitute progression, 2) 25% or greater increase in the percentage or plasma cells in the bone marrow biopsy, or 3) new bone lesions or an increase in the size of old lesions on x-ray. (NCT00581919)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 years.

Interventionmonths (Median)
Bort, Dex, and Dox With ALCAR5

[back to top]

Mean Arterial Blood Pressure

Mean Arterial blood pressure measured non-invasively at 18 hours (NCT00592488)
Timeframe: 18 hours

Interventionmm Hg (Mean)
Acetyl-L-Carnitine (ALC) Then Placebo60
Placebo Then Acetyl-L-Carnitine (ALC)60

[back to top]

Serum Lactate

Latest serum lactate between 12 and 36 hours (NCT00592488)
Timeframe: 12-36 hours

Interventionmg/dL (Mean)
Placebo Then ALC2.1
ALC Then Placebo2.0

[back to top]

Vasopressor Dose

Change in vasopressor dose between 6 and 24 hours. (NCT00592488)
Timeframe: 6-24 hours

Interventionmcg/kg/min (Mean)
Placebo Then ALC-1.4
ALC Then Placebo-4.8

[back to top]

Clinical Global Impression-Severity

"Scores could range from 0 - 7 units on a scale, with 0 representing the least severe (Normal, not at all ill) and 7 representing the most severe (Among the most extremely ill patients)." (NCT00719706)
Timeframe: Baseline to 15 weeks

,
Interventionunits on a scale (Mean)
Baseline DataEndpoint Data
ALCAR/ALA4.64
Placebo4.64.2

[back to top]

Phosphorus MRS Scans on 4T Scanner

Whole brain total NTP levels as measured by a phosphorus MRS scan on the 4T scanner. The data could range from 0 - 1, with 0 representing the lowest NTP level and 1 representing the highest NTP level. (NCT00719706)
Timeframe: Baseline to 12 weeks

,
Interventionunits on a scale (Mean)
Baseline DataWeek 1 DataEndpoint Data
ALCAR/ALA.230.229.229
Placebo.233.225.232

[back to top]

The 25-Item Hamilton Depression Rating Scale.

Scores could range from 0 - 72 units on a scale, with 0 representing the least number of depressive symptoms and 72 representing the most number of depressive symptoms. (NCT00719706)
Timeframe: Baseline to 15 Weeks

,
Interventionunits on a scale (Mean)
Baseline DataEndpoint Data
ALCAR/ALA23.317.5
Placebo22.118.5

[back to top]

The Montgomery-Asberg Depression Rating Scale

Scores could range from 0 - 60 units on a scale with 0 representing the least number of depressive symptoms and 60 representing the most number of depressive symptoms. (NCT00719706)
Timeframe: Baseline to 15 weeks

,
Interventionunits on a scale (Mean)
Baseline DataEndpoint Data
ALCAR/ALA26.919.6
Placebo25.921.7

[back to top]

The Young Mania Rating Scale

The scores could range from 0 - 60 units on a scale with 0 representing the least number of manic symptoms and 60 representing the most number of manic symptoms. (NCT00719706)
Timeframe: Baseline to 15 weeks

,
Interventionunits on a scale (Mean)
Baseline DataEndpoint Data
ALCAR/ALA21.7
Placebo2.42.1

[back to top]

12-week FACIT-fatigue Model-adjusted Score in ALC and Placebo Groups

Compare fatigue outcome between treatment and placebo groups as measured by the 13-item Functional Assessment of Chronic Illness Therapy FACIT-fatigue questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate more fatigue. Total possible range is 0 to 52. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

InterventionFACIT-fatigue score (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))36.6
Arm II (Placebo)35.3

[back to top]

12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups

Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

Interventionunits on a scale (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))35.4
Arm II (Placebo)36.3

[back to top]

12-week FACT-Trial Outcome Index(TOI) Functional Status Model-adjusted Score in ALC and Placebo Groups

Compare FACT-TOI outcome in treatment vs placebo groups at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse functional status. Total possible range is 0 to 120. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

Interventionunits on a scale (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))92.1
Arm II (Placebo)92.3

[back to top]

Proportion of Patients Experiencing Grade 3 or 4 Neuropathy

Proportion of patients experiencing grade 3 or 4 neuropathy (NCT00775645)
Timeframe: 12 weeks post-registration

InterventionParticipants (Count of Participants)
Arm I (Acetyl-L-carnitine Hydrochloride))8
Arm II (Placebo)1

[back to top]

C-Reactive Protein

C-Reactive Protein (CRP) was measured by a clinical laboratory. Measuring the quantity of serum CRP is helpful in recognizing inflammatory states. (NCT01054768)
Timeframe: 6 months

Interventionmg/l (Mean)
Alpha-lipoic Acid and Acetyl-L-carnitine11.4
Placebo6.8

[back to top]

Adverse Events

Incidence and severity of adverse events (NCT01537549)
Timeframe: at 25 weeks

InterventionNumber of Adverse Events (Number)
Juvenon23

[back to top]

Cerebral Oxidative Stress Markers

changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy (NCT01537549)
Timeframe: at baseline and at week 5

InterventionRatio (Mean)
Juvenon at Baseline4
Juvenon at 1 Month4.6

[back to top]

Days With Migraine and Side Effects

Secondary measures will be: Days with migraine; days with headache; hours with headache; headache intensity (0-3 scale) on days with headache; doses of analgesics; doses of triptans; days with sick leave; number of responders (≥ 50% decrease in migraine days compared with baseline); incidence of side effects recorded openly. (NCT01695317)
Timeframe: Last 4 weeks

InterventionHeadache hours per 4 weeks (Mean)
Acetyl-L-carnitine36.4
Sugar Pills37.0

[back to top]

Headache Days

The number of days per 4 weeks with moderate or severe headache lasting ≥ 4 hours or if treated with the patient's usual headache medication (usually a triptan) as the primary endpoint. (NCT01695317)
Timeframe: last 4 weeks

InterventionHeadache days per 4 weeks (Mean)
Acetyl-L-carnitine5.1
Sugar Pills5.2

[back to top]